765 results on '"Devogelaer, Jean-Pierre"'
Search Results
2. A Panel-Based Sequencing Analysis of Patients with Paget’s Disease of Bone Suggests Enrichment of Rare Genetic Variation in regulators of NF-κB Signaling and Supports the Importance of the 7q33 Locus
3. Sclerostin-Antibody Treatment Decreases Fracture Rates in Axial Skeleton and Improves the Skeletal Phenotype in Growing oim/oim Mice
4. Sclerostin antibody reduces long bone fractures in the oim/oim model of osteogenesis imperfecta
5. Randomised trial of genetic testing and targeted intervention to prevent the development and progression of Paget’s disease of bone
6. Genetic Variation in RIN3 in the Belgian Population Supports Its Involvement in the Pathogenesis of Paget’s Disease of Bone and Modifies the Age of Onset
7. Bone Turnover Markers and Glucocorticoid Treatments
8. Unmet needs and current and future approaches for osteoporotic patients at high risk of hip fracture
9. Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial
10. Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)
11. Effects of Dairy Products Consumption on Health: Benefits and Beliefs—A Commentary from the Belgian Bone Club and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
12. Bone Turnover Markers and Glucocorticoid Treatments
13. Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Biomarkers and Frailty
14. Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Epidemiology and Phenotype of Osteoarthritis
15. Postnatal growth defect in mice upon persistent Hoxa2 expression in the chondrogenic cell lineage
16. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate
17. Indications for a genetic association of a VCP polymorphism with the pathogenesis of sporadic Paget's disease of bone, but not for TNFSF11 (RANKL) and IL-6 polymorphisms
18. Is There a Place for Bone Turnover Markers in the Assessment of Osteoporosis and its Treatment?
19. Renal Expression of Parvalbumin Is Critical for NaCl Handling and Response to Diuretics
20. Remission Over 3 Years in Patients with Paget Disease of Bone Treated with a Single Intravenous Infusion of 5 mg Zoledronic Acid
21. Alternative Modes of Administration of Salmon Calcitonin in Paget’s Disease of Bone
22. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial
23. Bone Turnover Markers and Glucocorticoid Treatments
24. Health Technology Assessment in Osteoporosis
25. The majority of the genetic risk for Paget’s disease of bone is explained by genetic variants close to the CSF1, OPTN, TM7SF4, and TNFRSF11A genes
26. Biologicals in Osteoporosis: Teriparatide and Parathyroid Hormone in Women and Men
27. Gender-Related Impact of Sclerostin Antibody on Bone in the Osteogenesis Imperfecta Mouse
28. Founder Effect in Different European Countries for the Recurrent P392L SQSTM1 Mutation in Paget’s Disease of Bone
29. Characteristics of early Paget's disease in SQSTMI mutation carriers:baseline analysis of the ZIPP study cohort
30. Gender-Related Impact of Sclerostin Antibody on Bone in the Osteogenesis Imperfecta Mouse
31. Osteogenesis Imperfecta: Current Treatment Options and Future Prospects
32. Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club
33. Erratum to: Unmet needs and current and future approaches for osteoporotic patients at high risk of hip fracture
34. Dual Energy X-Ray Absorptiometry-Based Assessment of Male Patients Using Standardized Bone Density Values and a National Reference Database
35. Erratum to: Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Epidemiology and Phenotype of Osteoarthritis
36. Spontaneous rupture of the distal iliopsoas tendon: clinical and imaging findings, with anatomic correlations
37. Comparative Effect of Nimesulide and Ibuprofen on the Urinary Levels of Collagen Type II C-Telopeptide Degradation Products and on the Serum Levels of Hyaluronan and Matrix Metalloproteinases-3 and -13 in Patients with Flare-Up of Osteoarthritis
38. Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club
39. Evaluation of proposals of Belgian Social Security Institute for reimbursement of bone densitometry tests. Toward a costeffective strategy for osteoporosis screening?
40. Inhaled corticosteroids effects on bone in asthmatic and COPD patients: a quantitative systematic review
41. Ten years' experience with alendronate for osteoporosis in postmenopausal women
42. Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids
43. Modern Therapy for Paget’s Disease of Bone: Focus on Bisphosphonates
44. Tacrolimus and low-dose steroid immunosuppression preserves bone mass after renal transplantation
45. Inulin and fructo-oligosaccharides differ in their ability to enhance the density of cancellous and cortical bone in the axial and peripheral skeleton of growing rats
46. Glucocorticoid-Induced Osteoporosis: Mechanisms and Therapeutic Approach
47. Intravenous zoledronic acid in postmenopausal women with low bone mineral density
48. Characteristics of Early Paget's Disease inSQSTM1Mutation Carriers: Baseline Analysis of theZiPPStudy Cohort
49. The Pathogenesis of Glucocorticoid-Induced Bone Loss
50. Contributors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.